Is HRT Safe? What the Evidence Actually Says in 2026

The short answer: for most healthy women with bothersome menopausal symptoms who are under 60 or within about ten years of menopause, leading bodies including the Menopause Society and UK NICE conclude that the benefits of HRT generally outweigh the risks. HRT is not universally safe or universally risky; the balance is individual, depending on your age, health history, and the type, dose and delivery of hormones. The lasting fear largely traces to one 2002 study that has since been substantially reinterpreted, and in late 2025 US regulators moved to revise the decades-old boxed warning on many estrogen (oestrogen) products. The real risks, principally a small breast-cancer signal with combined HRT and a clot risk specific to tablets, are genuine but for most women small and manageable. None of this replaces a conversation with your own clinician.

If you have tried to work out whether HRT is safe, you have probably come away more confused than when you started. One account calls it a miracle every woman should be on. The next warns it causes cancer. Both are loud, both sound certain, and they cannot both be right. The confusion is the problem, not you. Hormone replacement therapy (HRT), also called menopausal hormone therapy, is one of the most studied and most misunderstood treatments in women’s health. Here is a calm, sourced look at what the evidence actually supports in 2026, what the recent change to US labelling means, and how to think about it for yourself.

What HRT is

HRT replaces some of the hormones, principally estrogen, and progesterone for women who still have a womb, that fall during menopause. It is used mainly to relieve symptoms such as hot flushes (hot flashes), night sweats, sleep disruption, mood changes and vaginal dryness, and it also has well-established effects on bone health. It comes in different forms, including tablets, skin patches, gels, sprays and vaginal preparations, which carry meaningfully different risk profiles, so “HRT” is not a single thing with a single safety verdict. Our companion guide, HRT Explained, covers the forms and types in more detail.

Where the fear came from

Much of the lasting fear traces back to the Women’s Health Initiative (WHI), a large US study whose initial findings in 2002 linked combined HRT to increased risks of breast cancer and heart disease. The headlines were dramatic, and HRT use fell sharply worldwide almost overnight, with many women stopping abruptly and many doctors becoming reluctant to prescribe. That single moment shaped a generation’s instincts about hormones, and its echo is still audible in the fear women bring to the subject today.

In the years since, researchers have substantially reinterpreted those findings. A key issue was that many WHI participants were older and further past menopause than the women who typically start HRT for symptoms, the average age was around 63, and the study largely used specific oral hormone types. Later analyses suggested the risk-benefit balance looks quite different depending on a woman’s age and how close she is to menopause, generally more favourable for those starting earlier. This reinterpretation, not a burying of inconvenient facts, is why professional bodies have updated their guidance.

What the evidence supports in 2026

Leading menopause organisations now take a more individualised position. The Menopause Society’s 2022 hormone therapy position statement concluded that for many healthy women under 60, or within about ten years of menopause, who have bothersome symptoms, the benefits of HRT generally outweigh the risks. UK NICE guidance (NG23) similarly supports HRT as an effective option for menopausal symptoms, to be considered alongside each woman’s individual risk factors. The word doing the work in both is individualised: HRT is not universally safe or universally risky, and the balance depends on your age, your health history, the type and dose of hormones, and how they are delivered.

There is also a “timing hypothesis” worth understanding: the evidence suggests starting HRT earlier in the transition, rather than many years after menopause, is associated with a more favourable balance, particularly for cardiovascular outcomes. Starting close to menopause appears not to carry the heart risks once feared and may even be neutral to favourable for the heart, whereas starting many years later is a different proposition. This is a large part of why specialists encourage women not to assume they must simply endure symptoms or wait until things are severe before discussing it.

What the recent US label change means

In late 2025, US regulators moved to revise the long-standing boxed warning that had appeared on many estrogen products for decades, a step widely reported and debated in the medical and general press. Supporters argued the old warning was based on outdated interpretations and had deterred women who could safely benefit; others cautioned against swinging too far the other way and understating genuine risks. Two things are worth holding at once. First, labelling and regulatory positions can change, so the current status is something to confirm with your clinician or pharmacist rather than assume from a headline. Second, a label change does not make HRT right for everyone; it changes the framing of a decision that still has to be made person by person.

The benefits, stated plainly

Because the conversation is so dominated by risk, it is easy to lose sight of what HRT actually does well, and honest content should state the benefits as plainly as the risks. HRT is the most effective treatment available for hot flashes and night sweats, and it commonly improves sleep, mood, brain fog, joint aches and vaginal and urinary symptoms at the same time, which for many women is the difference between struggling through the transition and functioning well. These are not trivial quality-of-life gains; for women with severe symptoms they can be transformative.

There are longer-term benefits too. Taken during the transition, estrogen preserves bone density and reduces the risk of fractures, including at the hip and spine, a meaningful benefit given how fast bone is lost around menopause, as our guide to bone density and menopause explains. For women with early menopause or premature ovarian insufficiency, HRT is particularly important and generally recommended at least until the average age of natural menopause, because it replaces hormones the body would otherwise still be producing. Weighing these genuine benefits against the risks, rather than considering risk in isolation, is what a balanced decision actually looks like.

The risks, stated plainly

HRT does carry risks, and honest content should say so clearly.

Breast cancer. Combined estrogen-plus-progestogen HRT is associated with a small increase in breast cancer risk that appears to relate to how long it is used, according to NHS and NICE summaries. Estrogen-only HRT, used by women without a womb, is associated with little or no increased risk in these summaries. The absolute increase for most women is small, comparable to or smaller than the effect of factors like drinking alcohol regularly or being overweight, and should be weighed against the benefits.
Blood clots. Oral (tablet) HRT is associated with a raised risk of blood clots. HRT delivered through the skin, as patches, gels or sprays, is not associated with the same increased clot risk in current guidance, which is a key reason delivery method matters and why transdermal routes are often preferred, especially for women with clot risk factors.
Individual contraindications. For some women, for example those with a history of certain hormone-sensitive cancers or specific clotting conditions, HRT may not be advised. This is precisely the kind of judgement a clinician makes with your full history, and it is why a general safety verdict cannot substitute for personal assessment.

Who HRT is and is not for

HRT is most often considered for women with troublesome menopausal symptoms, particularly those under 60 or within about ten years of menopause. It is not a general anti-ageing treatment, and the evidence does not support starting it purely to prevent conditions unrelated to menopause. Whether it is right for you depends on your symptoms, your health history and your own priorities, which is a discussion to have with a knowledgeable clinician rather than a decision to make from headlines or social media. For those who cannot or prefer not to take it, effective non-hormonal options exist, from prescription medicines for hot flashes to CBT and lifestyle measures.

How to have the conversation

Write down your main symptoms and how much they affect your daily life, so severity is clear.
Note your relevant history: family history of breast cancer or clots, your own medical conditions, and any medications.
Ask about the different types and delivery methods, and how they change the risk picture (for example, patch or gel versus tablet).
Ask what the current labelling and guidance say, so you are working from up-to-date information.
Ask how and when your treatment will be reviewed, since some adjustment in the first months is normal.

Our companion guides, HRT Explained and how to get an HRT prescription, are designed to help you walk into that conversation prepared rather than overwhelmed, and getting the most from your appointment helps if you have felt dismissed before.

Frequently Asked Questions

Is HRT safe in 2026?

For many healthy women under 60 or within about ten years of menopause who have bothersome symptoms, professional bodies including the Menopause Society and NICE consider the benefits of HRT to generally outweigh the risks. Safety is individual, depending on your age, health history and the type and delivery of HRT, so it should be assessed with your clinician rather than judged from a single headline. For most women in this group, the picture is far more reassuring than the old fear suggests.

Did regulators remove the warning on HRT?

In late 2025, US regulators moved to revise the long-standing boxed warning on many estrogen products, a step that was widely reported and debated. It reframes how the decision is presented rather than making HRT suitable for everyone. Regulatory positions can change, so confirm the current status with your clinician or pharmacist rather than relying on a headline, and treat it as one input into an individual decision rather than a blanket verdict.

Does HRT cause breast cancer?

Combined estrogen-plus-progestogen HRT is associated with a small increase in breast cancer risk that relates to duration of use, according to NHS and NICE. Estrogen-only HRT is associated with little or no increased risk in these summaries. For most women the absolute risk is small, on a similar scale to some everyday lifestyle factors, and is weighed against the benefits. Your personal and family history shape this, which is why it is assessed individually with your doctor.

Why does the delivery method (patch versus tablet) matter?

Because it changes the risk profile. Oral tablet HRT is associated with a raised risk of blood clots, whereas HRT absorbed through the skin as a patch, gel or spray is not associated with the same increased clot risk in current guidance. For this reason transdermal routes are often preferred, particularly for women with clot risk factors, migraine, or a higher BMI. This is one of the clearest examples of why “is HRT safe” cannot be answered without specifying the type and route.

Who should not take HRT?

HRT may not be advised for women with a history of certain hormone-sensitive cancers, some clotting disorders, active liver disease, or other specific conditions, and for these women non-hormonal options are considered instead. Only a clinician who knows your full medical history can tell you whether HRT is appropriate for you. Being in a higher-risk group does not always rule it out entirely, but it does mean the decision needs careful, individualised specialist input.

How long can I stay on HRT, and is longer riskier?

There is no fixed time limit, and the old rule that HRT must be stopped after a set number of years is outdated. The small breast-cancer signal with combined HRT does relate to duration of use, so length is part of the ongoing risk-benefit review, but many women continue for years under periodic review with their doctor, weighing continued symptom relief and bone benefits against changing risks. The key is regular reassessment rather than an arbitrary cut-off date.

more

Social Media

Subscribe to Our Newsletter